User login
Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.
Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).
Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.
Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.
Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.
Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).
Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.
Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.
Key clinical point: Pancreatic enzyme replacement therapy (PERT) administration in patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing standard first-line chemotherapy with gemcitabine plus nab-paclitaxel improved survival, along with weight gain and reduction in maldigestion-related symptoms.
Major finding: PERT administration was associated with longer overall survival (hazard ratio 2.85; P < .001), weight gain at 3 months (P = .02), and a significant reduction in feeling of indigestion (P = .001), bloating (P < .0001), frequent stools (P < .0001), and floating or greasy/fatty stool (P = .003).
Study details: This retrospective study included 110 patients with advanced PDAC treated with first-line chemotherapy with gemcitabine plus nab-paclitaxel with (n = 55) or without (n = 55) PERT administration.
Disclosures: No specific source of funding was identified for this study. Some investigators, including the lead author, reported receiving speaker’s fees, honoraria, travel expenses, consultant’s fees, and institutional research grants and participation in advisory boards and steering committee activities from various sources.
Source: Trestini I et al. Front Oncol. 2021(Sep 9).Doi: 10.3389/fonc.2021.688889.